gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TXMDHealthcarePharmaceuticals

TherapeuticsMD, Inc. (TXMD)

$1.82+2.25%
Close Nov 4, 2026 · split-adjusted
Oct 30, 2026$1.80▲ 51.26% in range
Oct 31, 2025Low $1.15 · High $2.77Oct 30, 2026
What changed · written from our data
As of Nov 4, 2026

TherapeuticsMD closed at $1.82 on Nov 4, up 2.25%, 34.3% below its 52-week closing high. Volume of 28.7K shares was 1.48× its 20-day average (above normal).

Split-adjusted performance: -9.9% over one month, -10.3% over six months, +58.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $869K, down 8.7% from a year earlier, with a net margin of 17.8%.

Short interest was 24.7K shares at the Oct 15 settlement, up 4.2% from the prior report (0.2% of float, 1.4 days to cover).

Market cap$21.1M11.6M shares
Revenue · quarter$869.0K−8.7% YoY
Diluted EPS$0.01−80.0% YoY
P/E · TTM—P/S 6.4×
Net margin17.8%Gross 100.0%
Dividend yieldNone
52-week range1.15 – 2.77−34.3% from high
Volume28.7K1.48× 20-day avg
Volatility · 60d34.2%Annualised
Short % of float0.2%1.4 days to cover
Net cash$9.2MCash $9.2M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.7%1M −9.9%3M −12.9%6M −10.3%YTD +11.7%1Y +58.3%3Y −12.1%5Y −95.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum64
Revenue growth34
Net margin85
Value (low P/E)—
Size22

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short24.7K+4.2% vs prior
Days to cover1.4Settled Oct 15
% of float0.2%
Short vol. 10d40.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TXMDTherapeuticsMD$1.82+2.25%−10.3%−8.7%17.8%—$21.1M
MCRBSeres Therapeutics$2.09+6.63%−73.9%—622.4%—$21.0MCompare
ATOSAtossa Therapeutics$2.12−9.01%−63.4%———$21.2MCompare
EDSAEdesa Biotech$2.17−4.82%−85.5%———$20.9MCompare
AYTUAYTU BioPharma$1.92−0.52%−25.0%+6.4%−0.1%—$20.9MCompare
IGCIGC Pharma$0.1950+4.84%−38.7%−19.2%−1107.9%—$20.2MCompare
COCPCocrystal Pharma$1.01−5.61%−28.4%—−3013.3%—$19.5MCompare
MIRAMIRA Pharmaceuticals$0.5610+8.34%−43.9%———$23.6MCompare
CRVOCervoMed$1.56+0.65%−59.3%−100.0%——$23.6MCompare

News about TherapeuticsMD

All news →

No recent articles focused on TherapeuticsMD.

Quick answers

What does TherapeuticsMD do?
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
What is TXMD's market cap?
$21.07M, based on the Nov 4 close of $1.82.
Does TherapeuticsMD pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TXMD is sold short?
24.7K shares, 0.2% of float, as of Oct 15, 2026.
What sector is TXMD in?
Healthcare, in the Pharmaceuticals industry.

About TherapeuticsMD

TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.

HQ: Boca Raton, FL1 employeesListed Jan 28, 2002therapeuticsmd.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology